ENLIGHTENED innovation.
Expansive therapeutic impact.
Outpacing conventional drug discovery to unlock the full potential of high value targets
Chemoproteomics is providing a new path to a universe of previously inaccessible therapeutic targets – yet drug discovery has remained inefficient, with patients waiting for new hope. Now, Jnana scientists are unlocking the full potential of chemoproteomics to uncover unique binding sites on highly validated protein targets and accelerate the discovery of new molecules that can change the course of disease.
Learn more about Jnana’s next-generation chemoproteomics drug discovery platform.
Learn more about Jnana’s next-generation chemoproteomics drug discovery platform.
Because time is of the essence
Patients today are in need of new medicines. Jnana’s RAPID platform allows us to systematically develop small molecule medicines for any target class with unmatched speed and efficiency. Together, we are advancing first- and best-in-class therapies to treat phenylketonuria (PKU) and a broad range of immune-mediated diseases and cancers.
Explore our pipeline programs and opportunities to partner.
Explore our pipeline programs and opportunities to partner.
Explore new horizons
Drug discovery is not for the faint of heart. Breakthroughs are achieved through perseverance, wisdom gained through experience, and possibility fueled by collaboration and the power of ideas.
Be part of something bigger. Find your role at Jnana.
Be part of something bigger. Find your role at Jnana.
Follow our progress
Nov 15, 2022
Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform
Nov 15, 2022
Jnana Therapeutics Announces Second Collaboration with Roche to Address Challenging-to-Drug Targets in Cancer, Immune-Mediated and Neurological Diseases
Jul 08, 2022